Full Press Release Details
Creative Medical Technology Holdings
Appoints Internationally Renowned Stem Cell Pioneer as Chief Scientific Officer
Clinical Stage Stem Cell Company to Accelerate
Product Development Leveraging Experience of
San Diego, CA, Phoenix, AZ, March 8, 2017
- Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today the appointment of Dr. Thomas Ichim to
the position of Chief Scientific Officer. Dr. Ichim will lead development of the Company's clinical stage CaverStemTM
personalized stem cell therapy for erectile dysfunction, as well as advance preclinical and eventually clinical studies on the
Company's universal donor AmnioStemTM stem cell therapy for post-stroke recovery.
"It is my honor to welcome Dr. Ichim
to the position of Chief Scientific Officer," said Timothy Warbington, President and CEO of CELZ. "I have known Dr.
Ichim for more than 10 years and have witnessed him grow his previous company, Medistem Inc., from concept to FDA Investigational
New Drug (IND) clearance, to eventual acquisition by the NYSE traded company Intrexon. I am confident that Dr. Ichim will put CELZ
on the same trajectory of success."
"Having published 20 peer-reviewed
papers with Dr. Ichim over the last nine years, I greatly respect his unique ability to rapidly accelerate progress from concept,
to patent, product. I look forward to continuing our collaborations in his new position," said Dr. Amit Patel, Cofounder
and Board Member of CELZ, and Head of Cardiac Surgery at University of Miami.
"Dr. Ichim represents a true visionary
in the area of cellular therapy, being one of the few people that effectively combines deep knowledge of basic science, regulatory
affairs, and clinical translation. I plan to leverage our existing strengths at the Pacific Neurosciences Institute and at St John
Providence to accelerate neurological uses of the Company's AmnioStemTM stem cell, particularly in the indication
of post-stroke recovery," said Dr. Santosh Kesari, MD, PhD, FANA, FAAN, Scientific Advisory Board Member of CELZ. Dr. Kesari
is Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, as well as
Director of Neuro-oncology, Providence Saint John's Health Center and leads the Pacific Neuroscience Research Center at Pacific
Neuroscience Institute.
"I am enthusiastic about working
with the distinguished team that Mr. Warbington assembled to accelerate clinical development of the Company's products,"
said Dr. Thomas Ichim, Ph.D. "This is one of those few occasions when one finds themselves in a position to work with people
that one respects both as individuals and as leaders in their fields."
Dr. Ichim has extensive experience with
stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over seven years as the Chief
Executive Officer, and subsequently, President and Chief Scientific Officer of Medistem, developing and commercializing a novel
stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through
Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr.
Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. Dr. Ichim has over
100 patents and patent applications, as well as 103 peer reviewed publication.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings,
Inc. is a clinical stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information
about the company go to www.creativemedicaltechnology.com.
Forward-Looking Statements
OTC Markets has not reviewed and does
not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements
including but not limited to comments regarding the timing and content of upcoming clinical trials, marketing efforts, funding,
etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties.
Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports
filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's
website at www.sec.gov.
Medical Technology Holdings, Inc.
Warbington, CEO & President
Barwicki, Investor Relations